AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26131788
Drug: Mobile training
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile training video for chemical nerve agent scenario
Trial: 21134121
Drug: 5u/mL BTX‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5u/mL BTX‐A
Trial: 12948920
Drug: 0.005% calcipotriol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.005% calcipotriol alone once daily (monotherapy)
Trial: 12948920
Drug: 0.004% calcipotriol/0.01%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.004% calcipotriol/0.01% clobetasol propionate as a premixed ointment once daily (combination therapy)
Trial: 30649257
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without any further treatment)
Trial: 29562486
Drug: Ice pack
RxNorm normalized name: Ice Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice pack therapy
Trial: 27573936
Drug: THCV (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THCV (5 mg twice daily)
Trial: 27573936
Drug: CBD (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (100 mg twice daily)
Trial: 27573936
Drug: Combination treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatments (1:1 ratio of CBD and THCV (5 mg/5 mg, twice daily) and 20:1 ratio of CBD and THCV (100 mg/5 mg, twice daily))
Trial: 23809278
Drug: Levonorgestrel (LNG)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel (LNG) 1.5 mg + meloxicam 15 mg
Trial: 20884177
Drug: Nifedipine CR
RxNorm normalized name: nifedipine Extended Release Oral Tablet [Afeditab CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine CR 40 mg
Trial: 20884177
Drug: Diltiazem R
RxNorm normalized name: R-348
DrugBank: R-348 (DB06321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem R 100 mg
Trial: 18203086
Drug: Latanoprost-timolol maleate
RxNorm normalized name: latanoprost / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost-timolol maleate fixed combination (LTFC) administered at 8 PM (Group 1)
Trial: 18203086
Drug: Latanoprost-timolol maleate
RxNorm normalized name: latanoprost / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost-timolol maleate fixed combination (LTFC) administered at 8 AM (Group 2)
Trial: 18203086
Drug: Latanoprost therapy
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost therapy alone (Control)
Trial: 9524791
Drug: Intramuscular meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular meloxicam (15 mg) on Day 1 followed by oral meloxicam (15 mg/day) for 7 days
Trial: 9524791
Drug: Intramuscular piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular piroxicam (20 mg) on Day 1 followed by oral piroxicam (20 mg/day) for 7 days
Trial: 3513719
Drug: Three injection
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three injection regimen (delaying evening intermediate acting insulin to bedtime)
Trial: 3513719
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin regimen (evening intermediate acting insulin before the evening meal)
Trial: 30585526
Drug: Primary radical
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary radical prostatectomy (RP) with extended pelvic lymph-node dissection and adjuvant or salvage radiation therapy (RT) and/or androgen deprivation therapy (ADT) if deemed necessary.
Trial: 30585526
Drug: Primary radiation
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary radiation treatment (RT) plus androgen deprivation treatment (ADT).
Trial: 20406214
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (200 ml t.i.d. for 5 days)
Trial: 17965148
Drug: Gabapentin 600
RxNorm normalized name: gabapentin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 600 mg single-dose
Trial: 10368494
Drug: Vaginal estradiol
RxNorm normalized name: estradiol Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal estradiol (2 mg twice daily)
Trial: 10368494
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol (2 mg twice daily)
Trial: 2015735
Drug: Temazepam, 30
RxNorm normalized name: Temazepam, 30 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam, 30 mg
Trial: 7089798
Drug: Coffee (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee (active drug)
Trial: 29781308
Drug: 0.05% clobetasol
RxNorm normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% clobetasol ointment
Trial: 18437470
Drug: Encouragement to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encouragement to resume daily physical activity with standardized advice and individualized activity goals
Trial: 18437470
Drug: Encouragement to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encouragement to resume daily physical activity
Trial: 11408507
Drug: HEC (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC (epirubicin 100 mg/m², cyclophosphamide 830 mg/m²; day 1 every 3 weeks)
Trial: 11408507
Drug: EC (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC (epirubicin 60 mg/m², cyclophosphamide 500 mg/m²; day 1 every 3 weeks)
Trial: 11408507
Drug: CMF (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF (oral cyclophosphamide for six cycles)
Trial: 9208358
Drug: Captopril (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (75 mg thrice daily)
Trial: 2626336
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate (50 mg/kg)
Trial: 386715
Drug: 6 g
RxNorm normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g L-tryptophan daily
Trial: 25049195
Drug: Treatment focusing
RxNorm normalized name: ficusin
DrugBank: Psoralen (DB18665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment focusing on weight and behavioral symptoms
Trial: 25049195
Drug: Treatment focusing
RxNorm normalized name: ficusin
DrugBank: Psoralen (DB18665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment focusing solely on improving QoL
Trial: 21056284
Drug: Orange juice
RxNorm normalized name: Orange juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orange juice (OJ) concentrate, 750 mL/day for 60 days
Trial: 15699477
Drug: gefitinib 250
RxNorm normalized name: gefitinib 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gefitinib 250 mg/d
Trial: 15699477
Drug: gefitinib 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gefitinib 500 mg/d
Trial: 9032097
Drug: Intraperitoneal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal insulin therapy (IP)
Trial: 7822993
Drug: Education on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education on diagnostic tests, chart audit, and feedback provided twice a week for first and second year residents; peer-review strategy for staff.
Trial: 3555162
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg epinephrine added to hyperbaric spinal bupivacaine
Trial: 25135124
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of oral melatonin administered at 9:00 pm for four consecutive days
Trial: 25135124
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at 9:00 pm for four consecutive days
Trial: 19933916
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy (3 or 4 cycles)
Trial: 16157231
Drug: Gabapentin (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (0 and 600 mg/day)
Trial: 1932484
Drug: Intravenous famotidine
RxNorm normalized name: Famotidine
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous famotidine (10 mg bolus followed by a constant infusion of 3.2 mg/h)
Trial: 1932484
Drug: Placebo (similarly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (similarly administered)
Trial: 7136659
Drug: Colostrum, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colostrum, 20 ml three times a day along with nursery formula
Trial: 30430667
Drug: Progressive muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive muscle relaxation therapy for 20 min and oral health education for 15 min before periodontal treatment once per week for 4 wk
Trial: 30430667
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education only for the same duration
Trial: 30430667
Drug: Progressive muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive muscle relaxation therapy
Trial: 30430667
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education only
Trial: 26898569
Drug: Mesalazine modified-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine modified-release tablets (MR group, n = 123)
Trial: 26898569
Drug: Mesalazine enteric-coated
RxNorm normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine enteric-coated tablets (EC group, n = 128)
Trial: 26898569
Drug: Mesalazine modified-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesalazine modified-release tablets (MR group)
Trial: 26898569
Drug: Mesalazine enteric-coated
RxNorm normalized name: mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine enteric-coated tablets (EC group)
Trial: 23034968
Drug: HFrAA (6.77
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFrAA (6.77 g of a mixture of 5 essential amino acids 3 times/d)
Trial: 23034968
Drug: HFr (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFr (3 g fructose · kg(‐1) · d(‐1) and maltodextrin placebo 3 times/d)
Trial: 15015000
Drug: Passive warming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive warming to rectal temperature of 39.5 degrees C
Trial: 11606169
Drug: Euglycaemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemia (blood glucose approximately 6 mmol/l)
Trial: 11606169
Drug: Hyperglycaemia (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemia (blood glucose approximately 14 mmol/l)
Trial: 8033186
Drug: 0.5 mg/ml
RxNorm normalized name: urea 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/ml Oolong tea extract (OTE) solution in 0.2% ethanol before and after every intake of food and before sleeping at night
Trial: 8033186
Drug: 0.5 mg/ml
RxNorm normalized name: urea 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/ml Oolong tea extract (OTE) solution
Trial: 2756357
Drug: Clindamycin and
RxNorm normalized name: clindamycin and benzoyl peroxide KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin and gentamicin (administered preoperatively as a single bolus infusion)
Trial: 2756357
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered preoperatively as a single bolus infusion)
Trial: 791330
Drug: labetalol (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol (average daily dose about 600 mg)
Trial: 18473792
Drug: DG17 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DG17 with sodium bicarbonate solution
Trial: 18473792
Drug: DG17 with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DG17 with low-dose ritonavir
Trial: 1384898
Drug: Cytotoxic/G-CSF mobilization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic/G-CSF mobilization
Trial: 29389579
Drug: Ankascin 568
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ankascin 568 plus (500 mg/day)
Trial: 26995799
Drug: SoluMatrix diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SoluMatrix diclofenac 35 mg
Trial: 26995799
Drug: SoluMatrix diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SoluMatrix diclofenac 18 mg
Trial: 26995799
Drug: Celecoxib 400
RxNorm normalized name: celecoxib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400 mg loading dose followed by 200 mg twice daily
Trial: 22892735
Drug: 2.5 mL
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL 1% peracetic acid (PAA)
Trial: 22892735
Drug: 2.5 mL
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL 17% EDTA
Trial: 22892735
Drug: 2.5 mL
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL 2.5% NaOCl + 2.5 mL 17% EDTA
Trial: 22892735
Drug: 2.5 mL
RxNorm normalized name: syringe, disposable, 2.5 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mL 0.5% PAA
Trial: 18460399
Drug: Teeth brushing
RxNorm normalized name: Coptis teeta root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teeth brushing plus tongue cleaning using a high speed vacuum ejector and irrigation with 20 ml antibacterial mouthwash
Trial: 18460399
Drug: Daily tongue
RxNorm normalized name: beef tongue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily tongue scraping
Trial: 12451982
Drug: Tablet Tongmaijiangzhi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet Tongmaijiangzhi (TTMJZ) 4 tablets, tid for 8 weeks
Trial: 12451982
Drug: Zocor 5
RxNorm normalized name: Zocor 5mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zocor 5 mg, qd for 8 weeks
Trial: 10613415
Drug: 117 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 117 mg/day of vitamin C during repletion phase
Trial: 10613415
Drug: 9 mg/day
RxNorm normalized name: EMSAM 9 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg/day of vitamin C during depletion phase
Trial: 24093506
Drug: Conventional balance
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional balance training according to physical therapy guidelines
Trial: 15026295
Drug: Medication adherence
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication adherence tracked with electronic cap monitors for 24 weeks
Trial: 10770980
Drug: High-fiber group
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fiber group (13.5 g per day of wheat-bran fiber)
Trial: 10770980
Drug: Low-fiber group
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fiber group (2 g per day of wheat-bran fiber)
Trial: 9007490
Drug: Dexamethasone (DEX)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEX) 0.25 mg/kg/12 h
Trial: 8024293
Drug: Topical inhaled
RxNorm normalized name: Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical inhaled corticosteroids (beclomethasone dipropionate 400 micrograms daily)
Trial: 3113712
Drug: Dibromomannitol (DBM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dibromomannitol (DBM) at a dose of 4 mg/kg
Trial: 23028103
Drug: cinacalcet plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cinacalcet plus low‐dose vitamin D (≤ 6 µg/week of intravenous paricalcitol equivalent)
Trial: 16774847
Drug: Self-selected treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-selected treatment (n=180)
Trial: 9539495
Drug: Abciximab (GP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abciximab (GP IIb/IIIa blocker), administered as a bolus and 12-hour infusion
Trial: 9539495
Drug: Abciximab (GP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abciximab (GP IIb/IIIa blocker)
Trial: 9539495
Drug: Low-dose, weight-adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose, weight-adjusted heparin regimen, early vascular sheath removal, and elimination of routine postprocedural heparinization
Trial: 9539495
Drug: Abciximab (24-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abciximab (24-hour preprocedural infusion)
Trial: 9539495
Drug: Other GP
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other GP IIb/IIIa inhibitors (eptifibatide, lamifiban, tirofiban)
Trial: 31665455
Drug: Liraglutide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (3 mg SQ daily)
Trial: 26806566
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (two sessions of live music-based relaxation exercises)
Trial: 22842777
Drug: Supervised implementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supervised implementation of the Oral health care Guideline for Older people in Long‐term care Institutions (OGOLI)
Trial: 12701987
Drug: Synthetic formulation
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic formulation of BNP (nesiritide)
Trial: 11045888
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sumatriptan orally at 0700 h
Trial: 11045888
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sumatriptan orally at 0700 h and 0100 h
Trial: 11045888
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sumatriptan orally at 1300 h
Trial: 8370699
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g ethanol/kg wt
Trial: 8370699
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g ethanol/kg wt
Trial: 8370699
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g ethanol/kg wt
Trial: 3522509
Drug: Piracetam (3300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (3300 mg daily for 12 weeks)
Trial: 29917140
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy of tamoxifen followed by exemestane
Trial: 29917140
Drug: Exemestane monotherapy
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exemestane monotherapy
Trial: 19176089
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (BTXA) injection into bilateral rectus muscle
Trial: 12807340
Drug: Hypericum cream
RxNorm normalized name: Hypericum oil
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum cream
Trial: 12807340
Drug: Hypericum cream
RxNorm normalized name: Hypericum oil
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum cream and vehicle
Trial: 27362506
Drug: 600 mg/d
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/d DHA
Trial: 26059084
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) + aspirin (ASA)
Trial: 17952272
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (G1) - 70.5 (45.1‐87.5) units of insulin/day
Trial: 17952272
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (G2) - 2 (0.6‐14.1) units of insulin/day
Trial: 17952272
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (G1)
Trial: 17952272
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (G2)
Trial: 11092514
Drug: Wine consumption
RxNorm normalized name: Wine grape
DrugBank: Wine grape (DB10634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wine consumption (190 mL red wine, 13% vol/vol ethanol, 5 days per week for 10 weeks)
Trial: 3893139
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% epinephrine applied twice daily for two weeks
Trial: 3893139
Drug: Oral indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral indomethacin 25 mg four times daily for one week
Trial: 3893139
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of indomethacin treatment in patients receiving topical epinephrine